gefitinib has been researched along with nadp in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (nadp) | Trials (nadp) | Recent Studies (post-2010) (nadp) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 21,608 | 25 | 3,484 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| An, K; Ishii, Y; Nishimura, Y; Yamada, H | 1 |
| Cheng, W; Hu, Y; Peng, P; Qiu, N; Sheng, R; Yuan, Y | 1 |
| Guo, Y; Huang, D; Ran, M; Tam, KY; Zhang, SL; Zhou, Y | 1 |
3 other study(ies) available for gefitinib and nadp
| Article | Year |
|---|---|
ATP serves as an endogenous inhibitor of UDP-glucuronosyltransferase (UGT): a new insight into the latency of UGT.
Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Alamethicin; Animals; Catalytic Domain; Cetomacrogol; Endoplasmic Reticulum; Gefitinib; Glucuronosyltransferase; Humans; Male; Microsomes, Liver; NADP; Quinazolines; Rats; Rats, Sprague-Dawley; UDP-Glucuronosyltransferase 1A9 | 2012 |
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2014 |
Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Glucosephosphate Dehydrogenase; Humans; Lung Neoplasms; NADP; Oxidation-Reduction | 2023 |